An Open-Label, Multicenter, Prospective, Interventional Study to Assess the Role of Pancreatic Enzyme Replacement Therapy (PERT) (Creon® 35,000) in Patients with Pancreatic Exocrine Insufficiency (PEI) after Pancreatic Surgery.
ENSAYO CLÍNICO CON MEDICAMENTOS
Información del ensayo clínico
- Promotor: MEDA PHARMA GMBH & CO
- Fase: III
- Comienzo de la ejecución: 20/01/2025
- Fin de la ejecución: 30/09/2025
- IP: MARIO SERRADILLA MARTIN